Illumina Corporation

Gen-probe, Inc.

Research Corporation Technologies, Inc.

Jorge Velarde

John R Stuelpnagel

Michael S Graige

David L Barker

Steven Mark Barnard

Todd C Peterson

Norman C Nelson

Daniel L Kacian

Ronald B Luftig

Danuta Pieniazek

Susan B Slemenda

Norman J Pieniazek

Steven M Bernard

The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture.

Compounds and method for representational selection of nucleic acids from complex mixtures using hybridization

Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization

The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture.

The present invention features compounds and methods for inhibiting propagation of human immunodeficiency virus (HIV). Preferred HIV target sites are identified and oligonucleotides designed to hybridize to a target site are described. The preferred use of the oligonucleotides is as an anti-HIV agent to inhibit HIV propagation in a patient infected with HIV. Other uses of the present invention include detecting the presence of HIV by using the oligonucleotides as detection probes or amplification primers, and measuring the ability of an oligonucleotide to inhibit HIV propagation to evaluate its suitability as an anti-HIV agent for a phenotype of HIV or diagnose the presence of HIV in a patient.

Oligonucleotides with activity against human immunodeficiency virus

The invention features a method for assaying the ability of an oligonucleotide to form a hybrid with a target nucleic acid sequence. The featured assay comprises the following steps: (a) contacting a test sample containing a target nucleic acid sequence with an oligonucleotide; (b) treating the test sample with a duplex-altering agent; (c) contacting the treated test sample with a labeled probe under stringent hybridization conditions, wherein the probe can hybridize to non-altered target nucleic acid sequence such that the probe label is protected from subsequent chemical inactivation but the probe cannot hybridize to altered target nucleic acid sequence in a manner which would protect the probe label from subsequent chemical inactivation; and (d) measuring the hybridization of the probe to non-altered target nucleic acid sequence by measuring the amount of protected label. Also described is an assay to measure the ability of a ribozyme to cleave a target nucleic acid sequence, and an assay to measure the ability of an agent to alter nucleic acid.

Oligonucleotide screening assay using DNA-altering agents and probes

The present invention relates to DNA and proteins of human adenovirus Type 41 and their use in detection of said virus. More specifically, the present invention relates to the isolation of a 41.4 kd short fiber protein and a 60.6 kd long fiber protein of adenovirus type 41 (Ad41), as well as proteins derived from the Ad41 E3 region, thereby providing virus-derived antigens and active derivatives and parts thereof, useful in the development of diagnostic assays, DNA probes and vaccines for said virus or other related viruses belonging to the human enteric adenovirus family. In addition, the present invention is directed to recombinant DNA molecules containing the human enteric adenovirus Type 41 Tak long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene (encoding the Ad41 proteins RL-1 to RL-6) thereby providing a source of recombinant viral components useful in the development of said diagnostic assays, DNA probes and vaccines for human adenoviruses. The present invention is also directed to first antibodies specific to the above-identified Ad41 viral components and to second antibodies specific to the first antibodies. These second antibodies are also useful in the development of diagnostic assays for Ad41 and other adenoviruses.

Detection of human adenovirus

Growing community of inventors

San Diego, CA, United States of America

Jorge Velarde